AnneCcile Fumey - Erytech Pharma HR Director
| ERYPDelisted Stock | USD 0.78 0.04 4.88% |
Insider
AnneCcile Fumey is HR Director of Erytech Pharma SA
| Age | 48 |
| Phone | 33 4 78 74 44 38 |
| Web | https://www.erytech.com |
Erytech Pharma Management Efficiency
The company has return on total asset (ROA) of (0.3014) % which means that it has lost $0.3014 on every $100 spent on assets. This is way below average. Erytech Pharma's management efficiency ratios could be used to measure how well Erytech Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Erytech Pharma SA currently holds 13.57 M in liabilities with Debt to Equity (D/E) ratio of 1.0, which is about average as compared to similar companies. Erytech Pharma SA has a current ratio of 2.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Erytech Pharma's use of debt, we should always consider it together with its cash and equity.
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. The company was incorporated in 2004 and is headquartered in Lyon, France. Erytech Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people. Erytech Pharma SA (ERYP) is traded on NASDAQ Exchange in USA and employs 49 people. Management Performance
| Return On Equity | -0.0098 | |||
| Return On Asset | -0.3 |
Erytech Pharma SA Leadership Team
Elected by the shareholders, the Erytech Pharma's board of directors comprises two types of representatives: Erytech Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Erytech. The board's role is to monitor Erytech Pharma's management team and ensure that shareholders' interests are well served. Erytech Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Erytech Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gil BVBA, CEO Director | ||
| Iman MD, Chief Officer | ||
| Philip Lorenzi, Consultant Board | ||
| AnneCcile Fumey, HR Director | ||
| Brian Schwab, Chief Counsel | ||
| Naomi Eichenbaum, Director Relations | ||
| Eric Soyer, CFO, COO | ||
| Bridget Bax, Consultant Board | ||
| Jrme PharmD, Chief Operations | ||
| Pr MD, Consultant Board |
Erytech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Erytech Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0098 | |||
| Return On Asset | -0.3 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (4.08) % | |||
| Current Valuation | 211.16 K | |||
| Shares Outstanding | 34.12 M | |||
| Shares Owned By Institutions | 7.65 % | |||
| Number Of Shares Shorted | 17.79 K | |||
| Price To Earning | (5.88) X | |||
| Price To Book | 0.65 X |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Erytech Stock
If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| CEOs Directory Screen CEOs from public companies around the world |